Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

Benzinga Newsdesk www.benzinga.com Positive 60.1%

Neg 0% Neu 0% Pos 60.1%

Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperform rating and announces Price Target of $6.